tirzepatide program Mission Family Medicine launches in-clinic Our Tirzepatide plan is now

Critical Data Points to Watch Revenue: $17.86 billion (+40.3% YoY) Adjusted EPS: $6.85 Mounjaro/Zepbound sales split and sequential growth Updated 2026 full-year revenue/profit guidance (consensus ~+25%) Actionable Ideas Bullish Scenario : Earnings beat + constructive guidance look for post-print strength or pullback entries with defined profit targets

Many researchers find these minor reactions lessen or disappear entirely as their protocol continues

Semaglutide was approved in 2017 and sold under the brand name Ozempic

Strength training can further aid by building muscle mass and boosting metabolic rate

Han et al., 2009)